Financial Performance - Net revenue for Q3 2024 was 190.0million,anincreaseof7.1177.5 million in Q3 2023[3] - Net patient revenue was 174.7million,up7.7162.3 million in Q3 2023, partly due to one additional business day[4] - Total net revenue for the nine months ended September 30, 2024, reached 559.571million,comparedto516.724 million for the same period in 2023, reflecting an increase of 8.3%[35] - Operating income for Q3 2024 was 1.129million,asignificantimprovementfromanoperatinglossof764 thousand in Q3 2023[35] - The company reported a net loss attributable to ATI Physical Therapy of 33.814millionforQ32024,comparedtoanetlossof15.197 million in Q3 2023[35] - Net loss for the nine months ended September 30, 2024, was 48,944,000,animprovementfromanetlossof61,570,000 for the same period in 2023[38] - The net loss available to common stockholders was 40.8million,comparedto18.3 million in Q3 2023[13] - The company reported a net loss of 32,869inQ32024,comparedtoanetlossof2,552 in Q2 2024[44] Revenue and Growth Metrics - Visits per Day (VPD) increased by 6.1% to 24,860 from 23,435 in Q3 2023, driven by higher clinical FTE and productivity[5] - For Q4 2024, the company projects revenue between 182millionand192 million, with Adjusted EBITDA expected to be between 9millionand14 million[20] - Net Patient Revenue for Q4 2023 was 166,145,representinga13.0196,610, a 12.5% increase compared to Q1 2024[42] Cost and Expense Management - Salaries and related costs increased by 8.7% to 105.6million,primarilyduetoaddedcliniciansandwageinflation[6]−Selling,general,andadministrativeexpensesdecreasedto23.772 million in Q3 2024 from 25.085millioninQ32023,showingcostmanagementefforts[35]−Cashpaidforinterestwas42,883,000, compared to 38,998,000inthepreviousyear,indicatinganincreaseininterestexpenses[39]LiquidityandFinancialPosition−TotalliquidityasofSeptember30,2024,was23.5 million, with a need for additional liquidity by early 2025[18] - Cash and cash equivalents decreased to 23,460,000from36,802,000, a reduction of about 36.5%[39] - Total assets decreased to 967,281,000asofSeptember30,2024,downfrom1,003,281,000 at December 31, 2023, representing a decline of approximately 3.6%[36] - Total current liabilities decreased to 143,662,000from156,447,000, a decrease of about 8.2%[36] - Long-term debt increased to 441,511,000from433,578,000, an increase of approximately 1.4%[36] - Net cash used in operating activities was 31,399,000fortheninemonthsendedSeptember30,2024,comparedto17,775,000 for the same period in 2023, indicating a worsening cash flow situation[38] Impairment and Fair Value Adjustments - Fair value remeasurement losses totaled 19.0million,comparedtoagainof1.9 million in Q3 2023, primarily due to share price increases[11] - The company faced a change in the fair value of 2L Notes amounting to 18.765millioninQ32024,comparedtoalossof1.485 million in Q3 2023[35] - The company reported a change in the fair value of 2L Notes resulting in a loss of 15,976,000forthequarter[45]−Thecompanyincurred5,591,000 in goodwill, intangible, and other asset impairment charges during the quarter[45] - The company faced a significant impairment charge of 96,038,000forgoodwillandintangibleassetsin2022[46]RegulatoryandMarketEnvironment−Thecompanyissubjecttoextensiveregulationandmacroeconomicuncertainty,whichmayimpactfutureperformanceandcompliance[27]EmployeeMetrics−Theheadcountturnoverratedecreasedto1656.68 in Q1 2024, down from 56.38inQ42023[42]AdjustedEBITDAandMargins−AdjustedEBITDAroseto12.1 million, a 28.8% increase from 9.4millioninQ32023,withanAdjustedEBITDAmarginof6.412,145, with an Adjusted EBITDA margin of 6.4%[44] - Adjusted EBITDA for Q2 2024 was 16,579,markingasignificantincreasefrom6,463 in Q1 2024[44] - Adjusted EBITDA for the quarter was 12,675,000,withanadjustedEBITDAmarginof7.06,363,000, with an adjusted EBITDA margin of 3.9%[46]